• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nine ?g intradermal influenza vaccine and 15 ?g intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults

tetano

Editor, Senior Moderator
Hum Vaccin Immunother. 2014 Jul 3:e29695. [Epub ahead of print]
Nine ?g intradermal influenza vaccine and 15 ?g intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.
Nolwenn N1, Bisceglia H, Rozi?res A, Goujon C, Boudet F, Laurent P, Vanbervliet B, Rodet K, Hennino A, Nicolas JF.
Author information
Abstract

Intanza? 9 ?g (Sanofi Pasteur), a trivalent split-virion vaccine administered by intradermal (ID) injection, was approved in Europe in 2009 for the prevention of seasonal influenza in adults 18 to 59 years. Here, we examined the immune responses induced in adults by the ID 9 ?g vaccine and the standard trivalent intramuscular (IM) vaccine (Vaxigrip? 15 ?g, Sanofi Pasteur). This trial was a randomized, controlled, single-center, open-label study in healthy adults 18 to 40 years of age during the 2007/8 influenza season. Subjects received a single vaccination with the ID 9 ?g (n = 38) or IM 15 ?g (n = 42) vaccine. Serum, saliva, and peripheral blood mononuclear cells were collected up to 180 days post-vaccination. Geometric mean hemagglutination inhibition titers, seroprotection rates, seroconversion rates, and pre-vaccination-to-post-vaccination ratios of geometric mean hemagglutination inhibition titers did not differ between the two vaccines. Compared with pre-vaccination, the vaccines induced similar increases in vaccine-specific circulating B cells at day 7 but did not induce significant increases in vaccine-specific memory B cells at day 180. Cell-mediated immunity to all three vaccine strains, measured in peripheral blood mononuclear cells, was high at baseline and not increased by either vaccine. Neither vaccine induced a mucosal immune response. These results show that the humoral and cellular immune responses to the ID 9 ?g vaccine are similar to those to the standard IM 15 ?g vaccine.
KEYWORDS:

adult; immunogenicity; intradermal influenza vaccine; intramuscular vaccination; trivalent influenza vaccine

PMID:
25483667
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25483667
 
Back
Top Bottom